logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Why Gilead's and Moderna's Stocks Rallied Today

Gilead Sciences Gilead ( GILD ) stock soared after market hours adding $11 to the $1.90 the stock had gained during trading hours. Investors' enthusiasm was raised when very promising results came out of a clinical trial for Gilead’s drug...

Read More

April 16, 2020

0

Kazia Therapeutics Product Paxalisib Beats Temozolomide in Overall Survival in Mid-Phase Trial

The US FDA Awards Fast Track Designation to Paxalisib for Glioblastoma  Kazia Therapeutics Ltd ( KZIA ) - an Australian oncology biotechnology company, announced that the United States FDA has granted Fast Track Designation ( FTD ) to Kazia’s paxalisib for glioblastoma,...

Read More

August 25, 2020

0

Exelixis and Aerie Have Good News

Exelixis & Aerie Have Good News Exelixis' Good News about Cabometyx Takeda Pharmaceuticals applied to the Japanese Ministry of Health, Labor and Welfare ( MHLW ) for approval to manufacture and to sell Exelixis’ ( EXEL ) product Cabometyx® (cabozantinib)...

Read More

April 25, 2019

0

Compugen: A New Important Patent from Europe and Much More

Compugen: In the NEWS Compugen ( CGEN ) was granted a new patent for the composition of COM701 or backup antibodies for the treatment of cancer by the European Patent Office ( EPO ). The EPO Patent No. 3295951 titled,...

Read More

April 22, 2020

0

Bluebird bio and Celgene: Encouraging Clinical Trial Results for Last Resort Multiple Myeloma Treatment

A Great Day for B luebird bio and Celgene Read the Clinical Trial Results for Myeloma What a Great Day! Jobs reaching the moon. Inflation not yet showing any concerning signs. A fiercely rebounding stock market. Those who are still...

Read More

May 3, 2019

0

The U.S. CDC Tells the 50 States to Prepare for COVID-19 Vaccines by the End of October

CDC Is Asking States to Prepare for COVID-19 Vaccines The U.S. Center of Disease Control and Prevention ( CDC ) has asked the 50 states' public health officials to be ready to distribute potential COVID-19 vaccines to high-risk people, healthcare...

Read More

September 3, 2020

0

Sanofi and GlaxoSmithKLine COVID-19 Vaccines are Advancing in Clinical Trial

Sanofi and GlaxoSmithKline Have COVID-19 Vaccines Advancing in Clinical Trial Sanofi ( SNY ) and GlaxoSmithKline ( GSK ) started Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine. The vaccine candidate developed by both firms uses the same recombinant...

Read More

September 3, 2020

0

Will the Bear Escape Tonight from the Market? Regeneron and Severe Asthma Patients Good News

The Stock Market The Confused and Confusing Stock Market The stock market is confused and confusing. No analysts’ speculations are materializing and no satisfactory explanations for the market’s agitation and selloff. Although not an unprecedented situation, what makes it strange...

Read More

May 9, 2019

0

Moderna: Speeding down the Road Towards Developing a Prophylactic Vaccine Against the Novel Coronavirus (SARS-CoV-2)

Moderna Submitted an IND for Its mRNA Vaccine Candidate for Novel Coronavirus  Moderna ( MRNA ) announced that it has submitted an Investigational New Drug ( IND ) application to the U.S. Food and Drug Administration (FDA) for its mRNA...

Read More

April 28, 2020

0

Advaxis: Why This Small Firm's Stock Outperformed on a Negative Market Day

Advaxis Outperformed on a Negative Market Day ADXS Outperformed Advaxis’ ( ADXS ) stock rallied today as the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on its product  AIM2CERV ( axalimogene filolisbac ). The product is in...

Read More

May 15, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 81
  • 82
  • 83
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy